Charles Schwab Investment Management Inc. Boosts Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Charles Schwab Investment Management Inc. raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,812,502 shares of the company’s stock after purchasing an additional 45,090 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Roivant Sciences were worth $33,272,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ROIV. GAMMA Investing LLC lifted its stake in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. US Bancorp DE increased its stake in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the period. Quarry LP lifted its position in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences during the third quarter valued at $35,000. Finally, Pier Capital LLC grew its holdings in shares of Roivant Sciences by 1.1% in the third quarter. Pier Capital LLC now owns 429,908 shares of the company’s stock worth $4,961,000 after purchasing an additional 4,821 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Activity

In other news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CIO Mayukh Sukhatme sold 412,584 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the completion of the sale, the executive now owns 18,836,547 shares in the company, valued at $226,980,391.35. This represents a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $10.66 on Monday. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market capitalization of $7.61 billion, a price-to-earnings ratio of -71.06 and a beta of 1.26. The company’s 50-day simple moving average is $10.81 and its two-hundred day simple moving average is $11.50.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

ROIV has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.